Ypsomed
VerifiedInnovative, high-quality and reliable products and services which allow patients to administer their own medication in a safe and simple way
Launch date
Employees
Ownership
Market cap
CHF1.8b
Net debt
(CHF31.6m)
Firm valuation
$2.0b (Public information from 2022)
Share price
CHF140.6 YPSN.SW
Bern Canton of Bern (HQ)
Deals in current and previous year:
Company information
Edit Launch date
Employees
Ownership
Market cap
CHF1.8b
Net debt
(CHF31.6m)
Firm valuation
$2.0b (Public information from 2022)
Share price
CHF140.6 YPSN.SW
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E |
|---|---|---|---|---|---|---|---|
| Revenues | - | 325m | 388m | 378m | 328m | 337m | 392m |
| % growth | - | - | 19 % | (3 %) | (13 %) | 3 % | 16 % |
| EBITDA | - | 72.5m | 79.2m | 98.3m | 51.7m | 54.2m | 85m |
| % EBITDA margin | - | 22 % | 20 % | 26 % | 16 % | 16 % | 22 % |
| Profit | - | 38.3m | 43.3m | 50m | 9.2m | 4.2m | 25m |
| % profit margin | - | 12 % | 11 % | 13 % | 3 % | 1 % | 6 % |
| EV / revenue | - | 6.2x | 4.0x | 3.8x | 4.4x | 5.4x | 4.6x |
| EV / EBITDA | - | 27.4x | 19.6x | 14.5x | 28.1x | 33.6x | 21.4x |
| R&D budget | 36m | 45m | 54m | 76m | - | - | - |
| R&D % of revenue | - | 14 % | 14 % | 20 % | - | - | - |
Source: Company fillings or news article
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
